Patents by Inventor Beatriz Lopez de Uralde Garmendia

Beatriz Lopez de Uralde Garmendia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase inhibitors
    Patent number: 7863310
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Timothy Alan Shepherd
  • Kinase inhibitors
    Patent number: 7767674
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: August 3, 2010
    Assignee: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Kinase inhibitors
    Patent number: 7652015
    Abstract: The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: January 26, 2010
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jesus Andres Blas de Blas, Alfonso De Dios, Kevin John Hudziak, Tiechao Li, Beatriz López De Uralde-Garmendia, Mary Margaret Mader, Michael Ray Myers, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
    Patent number: 7582638
    Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz López de Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Kinase Inhibitors
    Publication number: 20080306068
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: June 15, 2005
    Publication date: December 11, 2008
    Applicant: Eli Lilly and Company
    Inventors: Tiechao Li, Mark Andrew Pobanz, Chuan Shih, Yong Wang, Boyu Zhong, Jesus Andres Blas, Alfonso De Dios, Beatriz Lopez De Uralde-Garmendia, Luisa Maria Martin Cabrejas
  • Kinase Inhibitors
    Publication number: 20080269244
    Abstract: The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 25, 2006
    Publication date: October 30, 2008
    Inventors: Jolie Anne Bastian, Jesus Andres Blas de Blas, Alfonso De Dios, Kevin John Hudziak, Tiechao Li, Beatriz Lopez De Uralde-Garmendia, Mary Margaret Mader, Michael Ray Myers, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
  • Kinase Inhibitors
    Publication number: 20080227839
    Abstract: The present invention provides kinase inhibitors of Formula I:
    Type: Application
    Filed: January 21, 2005
    Publication date: September 18, 2008
    Inventors: Rosanne Bonjouklian, Robert Dean Dally, Alfonso de Dios, Mirian Filadelfa del Prado Catalina, Carmen Dominguez-Fernandez, Carlos Jaramillo Aguado, Beatriz Lopez de Uralde-Garmendia, Carlos Montero Salgado, Timothy Alan Shepherd
  • Benzimidazoles and benzothiazoles as inhibitors of map kinase
    Patent number: 7320995
    Abstract: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rosanne Bonjouklian, Jose Eugenio De Diego Gomez, Alfonso De Dios, Chafiq Hamdouchi Hamdouchi, Tiecho Li, Beatriz Lopez De Uralde Garmendia, Michal Vieth, Jeremy Schulenberg York, Robert Dean Dally, Miriam Filadelfa Del Prado Catalina, Carlos Jaramillo Aguado, Luisa Maria Martin-Cabrejas, Carlos Montero Salgado, Sheila Pleite Selgas, Concepcion Sanchez-Martinez, Timothy Alan Shepherd, James Howard Wikel
  • Thiophene-and thiazolesulfonamides as antineoplastic agents
    Patent number: 7250430
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: July 31, 2007
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Thiophene-and thiazolesulfonamides as antineoplastic agents
    Publication number: 20060223871
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Application
    Filed: June 6, 2006
    Publication date: October 5, 2006
    Inventors: Cora Grossman, Philip Hipskind, Ho-Shen Lin, Karen Lobb, Beatriz Lopez de Uralde Garmendia, Jose Lopez, Mary Mader, Michael Richett, Chuan Shih, Alfonso De Dios
  • Thiophene-amd thiazolesulfonamides as antineoplastic agents
    Patent number: 7084170
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: August 1, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Excitatory amino acid receptor modulators
    Patent number: 7081481
    Abstract: Compounds of the formula (I) in which: R1 is (CH2)nY; n is 1 or 2; Y is NHSO2R2 or X1—W—X2—R3; X1 is O or NH; W is C?O, C?S, C?NH, or SO2; X2 is O or NH, provided that X1 and X2 are not both O; R2 is C1-10 alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10alkynyl; C3-8 cycloalkyl or C3-8-cycloalkyl-C1-10 alkyl; and R3 is hydrogen, C1-10alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10 alkynyl; C3-8 cycloalkyl; or C3-8-cycloalkyl-C1-10 alkyl; or a salt or ester thereof, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: July 25, 2006
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado-Cano, Maria Rosario Gonzalez-Garcia, Beatriz López De Uralde-Garmendia
  • Thiophene-amd thiazolesulfonamides as antineoplastic agents
    Publication number: 20040198784
    Abstract: The present invention provides antineoplastic compounds of the formula (D).
    Type: Application
    Filed: March 26, 2004
    Publication date: October 7, 2004
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso de Dios
  • Excitatory amino acid receptor modulators
    Patent number: 6498180
    Abstract: Compounds of formula (I) in which R1 is halo-C1-10 alkyl; halo-C2-10 alkenyl; or (CH2)nY in which n is 1 or 2 and Y is OH, CN, N3, OR3, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-tetrazol-5-yl, 5-phenyltetrazol-2-yl or PO3H2; R3, R5, R6, R7, R8 and R9 are each selected independently from C1-4 alkyl, aryl and aryl-C1-4 alkyl; R4 is selected from C1-4 alkyl, aryl, aryl-C1-4 alkyl, and 1H-tetrazol-5-yl, carboxy-(1-4C)alkyl and 1H-tetrazol-5-yl-C1-4 alkyl; and p is 0, 1, 2 or 3; or a salt or ester thereof, provided that R1 is not methoxymethyl, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: December 24, 2002
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Concepcion Pedregal Tercero, Alicia Marcos Llorente, Beatriz Lopez de Uralde Garmendia, Maria Rosario Gonzalez Garcia, Ana Belen Bueno Melendo